Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - piperacillin; tazobactam - powder for solution for infusion - 2g / 0.25 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

as kalceks - piperacillin; tazobactam - powder for solution for infusion - piperacillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

as kalceks - piperacillin; tazobactam - powder for solution for infusion - piperacillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - piperacillin; tazobactam - powder for solution for infusion - 4 g/0.5 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - piperacillin; tazobactam - powder for solution for infusion - 4 g/ 0.5 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

stravencon ltd - piperacillin sodium; tazobactam sodium - powder for solution for infusion - 4/0.5 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

United States - English - NLM (National Library of Medicine)

mylan institutional llc - piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx), tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w) - piperacillin anhydrous 2 g in 10 ml - piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis , b. ovatus , b. thetaiotaomicron , or b. vulgatus . piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of staphylococcus aureus and by piperacillin/tazobactam-susceptible acinetobacter baumannii , haemophilus influenzae , klebsiella pneumoniae , and pseudomonas aeruginosa (nosocomial pneumonia caused by p. aeruginosa should be treated in combination with an aminoglycoside) [see dosage and administration (2)]. piperacillin and tazobactam for injection is indicated in adults for the treatment of uncomplic

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx), tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w) - piperacillin anhydrous 2 g in 10 ml - piperacillin and tazobactam for injection, usp is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis , b. ovatus , b. thetaiotaomicron , or b. vulgatus . piperacillin and tazobactam for injection, usp is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of staphylococcus aureus and by piperacillin/tazobactam-susceptible acinetobacter baumannii , haemophilus influenzae , klebsiella pneumoniae , and pseudomonas aeruginosa (nosocomial pneumonia caused by p. aeruginosa